TScan Therapeutics Reports Third Quarter 2024 Financial
Quarterly Statements / Half-Year Reports - Bayer
2024. Q1. Q2. Q3. Presentation. View Document (2.1 MB), View Document (1.8 MB), View Document (2.6 MB). Financial Report.
TScan Therapeutics: Buy Rating Backed by Strong Clinical Results ...
In a report released today, Gil Blum from Needham maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), ...
TScan Therapeutics - Longwood Fund
TScan has closed two rounds of financing totaling $48 million from Longwood Fund, Google Ventures, Novartis Venture Fund, Bessemer Venture Partners, 6 ...
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
Key financial metrics show that BioXcel Therapeutics recorded net revenue of $214 thousand for the third quarter of 2024, a decrease from the ...
During the third quarter, TScan advanced a lead TCR-T therapy candidate for its TSC-200 program for HPV16 into investigational new drug (IND)-enabling ...
TScan Therapeutics Inc. (NASDAQ: TCRX) Stock Information
At close: Nov 14, 2024, 4:00 PM EDT. TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T ...
TScan Therapeutics on X: "Today we reported third quarter financial ...
Today we reported third quarter financial results and provided a corporate update. Read the press release to learn more about our recent ...
TScan Therapeutics - Crunchbase Company Profile & Funding
TScan Therapeutics reported its first quarter 2024 earnings, which missed expectations. The company also announced updates to its Board of Directors and ...
Public | Your Web Disclosure Platform
Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) · TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate ...
TCRX SEC Filings - TScan Therapeutics, Inc.- Annual Report, Proxy ...
Press Releases (Most Recent) ; 2023-08-10, TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary ...
TScan Therapeutics (TCRX)major events announcements - Futubull
TScan Therapeutics | 8-K: TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update. Aug 12 04:20.
TScan Therapeutics Inc, TCRX:NMQ summary - FT.com - Markets data
Key statistics · TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update · TScan Therapeutics Announces Upcoming Oral ...
Earnings call: BioXcel Therapeutics reports Q3 2024 financials
Net loss in Q3 2024 was significantly reduced to $13.7 million from $50.5 million in Q3 2023. Cash and cash equivalents stood at $40.4 million ...
TScan Therapeutics, Inc. (TCRX) Stock Price, Quote, News & Analysis
TScan Therapeutics, Inc. is expected to issue its next earnings report on 03/07/2025. In the previous quarter, TScan Therapeutics, Inc. reported $-0.25 (diluted) ...
On November 12, 2024, TScan Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, ...
Press Release - Category Reports | ResearchPool
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update by GlobeNewsWire · Creative Realities to ...
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 ...
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update ; Revenue: Collaboration and license ...
CARGO Therapeutics Reports Third Quarter 2024 Financial Results ...
Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2024 were $35.9 million and $103.9 ...
TScan Therapeutics, Inc. SEC 10-Q Report - TradingView
Collaboration and license revenue: $1.0 million, decreased from $3.9 million in Q3 2023 primarily due to the timing of research activities ...
Acrivon Therapeutics : Reports Third Quarter 2024 Financial Results ...
As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $202.8 million, which is expected to fund our ...